Cytomegalovirus (Treatment)

Vitrasert Implant Cleared for Marketing in European Union

Published in AIDS Weekly, April 14th, 1997

Chiron Vision, Claremont, California, a business of Chiron Corp., Emeryville, California, announced that the European Commission has granted a marketing authorization for the Vitrasert Implant in all 15 countries of the European Union.

The market clearance follows a recommendation of approval for the Vitrasert Implant by the Committee for Proprietary Medicinal Products (CPMP), which reviewed the product on behalf of the European Agency for the Evaluation of Medicinal Products (EMEA). The Vitrasert Implant is the first drug delivery system to provide local, sustained therapy of the eye for the treatment of cytomegalovirus (CMV) retinitis in people with AIDS.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1997-04-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry